REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search-icon
stethoscope
Etai Adam

Dr. Etai Adam, MD

  • MD
Department:
  • Pediatric Hematology
  • Oncology and Bone Marrow Transplant
Specialties:
  • Pediatrics
  • Pediatric Hemato-Oncology
  • Pediatric Bone Marrow Transplant
Languages:
  • English
  • Hebrew

About

Dr. Etai Adam is a senior physician at Sheba’s Pediatric Hemato-Oncology Division and Bone Marrow Transplantation Department. Completing his medical studies at Tel Aviv University’s Sackler School of Medicine, he currently focuses on hematopoietic stem cell transplants for non-malignant diseases, including inherited immune deficiencies, bone marrow failure syndromes, metabolic disorders, and acquired aplastic anemia.

Conditions and treatment

  • Hematopoietic stem cell transplant
  • One marrow failure syndrome
  • Aplastic anemia
  • Bone marrow transplant
  • Inherited immune deficiencies
  • Mtabolic diseases
  • Allogeneic transplant
  • Lymphoma

Positions

  • Senior Physician, Pediatric Hemato-Oncology Division and Bone Marrow Transplant

Education and Training

  • Clinical Fellow Safra Children’s Hospital, Pediatric Hematology and Oncology
  • Clinical Fellow, CHLA, Division of Hematology, Oncology, and BMT
  • Chief Resident, CHLA, Department of Pediatrics
  • Resident Physician, CHLA, Department of Pediatrics
  • MD Sackler School of Medicine, Tel Aviv University

Board Certifications

  • Pediatrics
  • Pediatric Hematology/Oncology

Publications

Ollech A, Mashiah J, Lev A, Simon AJ, Somech R, Adam E, Barzilai A, Hagin D, Greenberger S. Treatment options for DOCK8 deficiency-related severe dermatitis. J Dermatol. 2021 May 27. doi: 10.1111/1346-8138.15955. Epub ahead of print. PMID: 34043252.

Wittmann Dayagi, T.; Sherman, G.; Bielorai, B.; Adam, E.; Besser, M.J.; Shimoni, A.; Nagler, A.; Toren, A.; Jacoby, E.; Avigdor, A. (2021) Characteristics and risk factors of infections following CD28- based CD19 CAR-T cells, Leukemia & Lymphoma, 62:7, 1692-1701, DOI: 10.1080/10428194.2021.1881506

Hutt D, Bielorai B, Baturov B, Z’orbinski I, Ilin N, Adam E, Itzhaki O, Besser MJ, Toren A, Jacoby E. Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients. Transfus Apher Sci. 2020 Aug;59(4):102769. doi: 10.1016/j.transci.2020.102769. Epub 2020 Apr 25. PMID: 32414613.

Adam E., Jubran R., Weitzman S. (2018) Epidemiology and Clinical Manifestations of Langerhans Cell Histiocytosis in Children. In: Abla O., Janka G. (eds) Histiocytic Disorders. Springer, Cham.

Adam, E.; Kim, H N.; Gang, E. J.; Schnair, C.; Lee, S. et al. The PI3Kδ Inhibitor Idelalisib Inhibits.Homing in an in Vitro and in Vivo Model of B ALL. Cancers 2017, 9(9)

Adam E, Jubran R, Weitzman S. Epidemiology and clinical manifestations of LCH in children. In: Histiocytosis. Springer, August 2017.

Adam E, Church JA. Antibody Levels to Bordetella pertussis and Neisseria meningitidis in Immunodeficient Patients Receiving Immunoglobulin Replacement Therapy. Journal of Clinical Immunology. 2015; 35: 213-217.

Adam E, Wang L, Herrington C, Bliss D, Church JA. Synchronous HIV/AIDS-Related EBV-Associated Smooth Muscle Tumors in a 20-Year-Old Female. Pediatr Infect Dis J 2014; 33:1055–1056.

Request a consultation

Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.

We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.

Request a consultation and a Sheba Case Manager will contact you shortly: